Pediatrix Medical Group, Inc. (MD) reported third-quarter 2025 adjusted earnings per share of 67 cents, beating estimates by 45.7%, with a 52.3% increase year over year. Net revenues fell 3.6% to $492.9 million, surpassing estimates by 1.8%. Higher collection activity and reduced operating expenses contributed to the positive results.

Same-unit revenues climbed 8% year over year, driven by patient volume, while net reimbursement-related factors grew 7.6% due to improved patient acuity. Operating expenses decreased by 11% year over year to $424.8 million. Practice salaries and benefits fell by 8.9% to $332.3 million.

Pediatrix Medical ended the quarter with $340.1 million in cash and cash equivalents, a 47.9% increase from the previous year. Total assets rose to $2.2 billion, while total debt decreased to $602.5 million. Shareholders’ equity improved by 16.4% to $890.7 million.

The company repurchased $20.9 million worth of common shares in the first nine months of 2025, with $229.1 million remaining under its repurchase program. Management raised adjusted EBITDA and net income guidance for 2025, with interest expenses projected at $36.16 million and income tax expenses between $57.61-$63.01 million.

Pediatrix Medical Group, Inc. (MD) currently holds a Zacks Rank #3 (Hold). Key picks in the medical sector include McKesson Corporation (MCK), Universal Health Services, Inc. (UHS), and Veracyte, Inc. (VCYT), each with a Zacks Rank #1 (Strong Buy). Analysts project significant growth potential for these stocks in the near future.

Read more at Nasdaq: Pediatrix Medical Q3 Earnings Beat Estimates on Declining Expenses